2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

News

Bolder BioTechnology to Present Preclinical Data for Three Research Programs at Acute Radiation Syndrome Meeting

Boulder, Colorado – October 24, 2018- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting being held October 25, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland.…
Read more

Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference

Boulder, Colorado – September 6, 2018 – Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, gave an oral presentation at the “Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency” meeting held August 30, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center,…
Read more

Bolder BioTechnology Announces Publication of Preclinical Studies of BBT-059, a Long-Acting IL-11 Analog, in Mouse Models of the Hematopoietic Acute Radiation Syndrome

Boulder, Colorado – September 5, 2018 – Bolder BioTechnology, Inc. announced today publication of preclinical studies of BBT-059, a long-acting interleukin -11 (IL-11) analog, in mouse models of the hematopoietic acute radiation syndrome. The studies were performed in collaboration with researchers at the Armed Forces Radiobiology Research Institute (AFRRI), the Uniformed Services University of the…
Read more

Bolder BioTechnology Announces Presentation at the 2018 Military Health System Research Symposium

Boulder, Colorado - August 24, 2018  – Bolder BioTechnology is pleased to announce that Dr. Sanchita P. Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, was selected to give an oral presentation on preclinical studies of BBT-059, Bolder BioTechnology’s long-acting interleukin-11 analog, at the Military Health…
Read more